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A B S T R A C T
Objectives: Even with advanced image guidance, biopsies occasionally fail to diagnose small lung lesions, which
are highly suggestive of primary lung cancer by radiological examination. The aim of this study was to evaluate
the outcome of stereotactic body radiotherapy (SBRT) to treat small lung lesions clinically diagnosed as primary
lung cancer.
Materials and methods: This is a prospective, multi-institutional observation study. Strict inclusion and exclusion
criteria were determined in a nation-wide consensus meeting and used to include patients who were clinically
diagnosed with primary lung cancer using precise imaging modalities, for whom further surgical intervention
was not feasible, who refused watchful waiting, and who were highly tolerable of SBRT with informed consent.
SBRT was performed with 48 Gy in 4 fractions at the tumor isocenter.
Results: From August 2009 to August 2014, 62 patients from 11 institutions were enrolled. Their median age was
80 years. The tumors ranged in size from 9 to 30mm in diameter (median, 18mm). The median follow-up
interval was 55 months. The 3-year overall survival rate was 83.3% (95% conﬁdence interval (CI) 71.1–90.7%)
for all the patients and 94.7% (95% CI 68.1–99.2%) for the patients younger than 75 years. Local failure,
regional lymph node metastases and distant metastases occurred in 4 (6.4%), 3 (4.8%) and 11 (17.7%) patients,
respectively. Grades 3 and 4 toxicities were observed in 8 (12.9%) patients and 1 (1.6%) patient, respectively. No
grade 5 toxicities were observed.
Conclusions: SBRT is safe and eﬀective for patients with small lung lesions clinically diagnosed as primary lung
cancer that satisﬁed the proposed strict indication criteria as previously reported. A prospective interventional
study is required to ascertain if SBRT is an alternative strategy for these patients.
https://doi.org/10.1016/j.lungcan.2018.05.025
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Pathological diagnosis is essential to treat primary lung cancer.
However, biopsy occasionally fails to diagnose small lung lesions that
are highly suggestive of primary lung cancer. Additionally, biopsy and
diagnostic surgery are often not feasible due to medical complications
or are refused by elderly patients. Recently, Detillon et al. showed that
the mortality rate is 6.0% for patients 80 years or older who received
surgical lung cancer resection [1]. Damhuis et al. reported that post-
operative mortality increased with age: 1.7% for patients< 60 years
old versus 9.4% for patients of 80 years or older using data from the
Rotterdam and Thames Cancer registries and a prediction model [2].
Occasionally physicians recommend watchful waiting until the nodule
grows. In patients who receive watchful waiting, those with cancer are
at high risk of tumor progression.
Stereotactic body radiation therapy (SBRT) with a high local dose
has been applied to peripheral lung cancers and provides excellent
survival beneﬁt for both operable and inoperable cases [3,4]. We have
previously described a national retrospective SBRT study of patients
with clinically diagnosed primary lung cancer by radiological ex-
amination in 12 institutions [5]. The study showed that the 3-year
overall survival rate (OS) was 89.8% and that the grade 2 or higher
pulmonary adverse reaction rate was 3.4% in patients with a tumor
diameter≤ 20mm. To conﬁrm these results, strict eligibility and ex-
clusion criteria were made, and a prospective, nation-wide, multi-in-
stitutional SBRT observational study was performed. This is the ﬁnal
report describing that study.
2. Materials and methods
2.1. Study design and participants
The eligibility and exclusion criteria for SBRT to treat primary lung
cancer clinically diagnosed by radiological examination were de-
termined at the nation-wide consensus meeting attended by pulmo-
nologists, radiologist, and oncologist from institutes in JCOG 0403 [4]
and JCOG0702 [6,7]. All of the following criteria were required for a
patient to be eligible: (a) tumor diameter was ≤30mm; (b) biopsy by
bronchoscope or CT was attempted once or more but failed to diagnose
the lesion; the biopsy was refused or was unable to be performed be-
cause of medical complications; either the (c1) tumor size was enlarged
on sequential CT examination and ﬂuorine-18 ﬂuorodeoxyglucose
(FDG) positron emission tomography (PET) was also positive, or (c2)
for a ground-glass nodule (GGN) with a negative FDG PET, the pure
GGN tumor size was 10mm or larger and enlargement on sequential CT
examination, or a GGN had the appearance of a solid component; (d)
surgery was contraindicated or refused; (e) watchful waiting was re-
fused; (f) the Eastern Cooperative Oncology Group performance status
was 0–2; (g) patient age was ≥20 years; (h) dose constrains of all or-
gans at risk were expected to be fulﬁlled; (i) there was no history of
irradiation to the thorax; (j) PaO2≥ 60 Torr (under room air); (k)
forced expiratory volume 1.0≥ 700ml; and (l) written informed con-
sent was obtained.
The rationale for the (c2) criterion where a pure GGN tumor size
10mm or larger and enlargement on sequential CT examination is
following. When the nation-wide consensus meeting mentioned above
was held, this subgroup had been recognized to have a high frequency
of bronchioloalveolar carcinoma or invasive adenocarcinoma, sampling
error on percutaneous biopsy, and false negative PET ﬁndings and was
recommended to be surgically resected, as reviewed by Godoy and
Naidich afterwards [8]. In fact, Lim et al. recently conﬁrmed that 39%
of pure GGN 10mm or larger by CT were invasive adenocarcinomas by
pathology [9].
Exclusion criteria were as follows: (a) apparent interstitial pneu-
monia or pulmonary ﬁbrosis on the chest ﬁlm; (b) active infectious
disease; (c) synchronous or metachronous cancer within 2 years; (d)
pregnancy; (e) severe psychological disorder; (f) continuous systemic
steroid administration; or (g) continuous O2 inhalation. Patients were
excluded if they had any of these conditions.
2.2. Procedures
All the patients were irradiated using SBRT techniques. Three-di-
mensional treatment planning was performed using non-coplanar static
ports or dynamic arcs. The clinical target volume was exactly the same
as the gross tumor volume. Various techniques using breathing control
or gating methods and immobilization devices were utilized to reduce
internal margins. The internal margin, which varies by technique, and a
5mm setup margin were added to create the planning target volume
(PTV).
A total dose of 48 Gy at the isocenter was administered in 4 fractions
over 4–8 days, which is the same as the schedule used in JCOG0403 [4].
X-rays of 4–6MV were allowed. A heterogeneity correction calculation
was used. The position of the multileaf collimator sets was usually the
PTV plus a 5mm margin such that the PTV was mostly covered by the
80% isodose line. The dose constraints of the organs at risk were the
same in JCOG0403.
The primary endpoint was 3-year OS. Secondary endpoints included
OS, progression-free survival (PFS), local control rate (LC), toxicity and
patterns of failure. OS was deﬁned as the time from the date of regis-
tration to the date of death due to any cause and censored at the date of
the last follow-up for surviving patients. PFS included local failures,
regional lymph node failures, distant metastases and all deaths as
events and was censored at the last date without any events. LC in-
cluded only local failures as events and was censored at the last date
without local failure.
Patients were followed up with basic CT examinations at 2, 4, 6, 9
and 12 months after treatment and every 6 months thereafter for at
least 3 years until the end of the study. Toxicity was evaluated using the
Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Distinguishing between residual tumor tissue and radiation ﬁbrosis was
diﬃcult; therefore, the Response Evaluation Criteria in Solid Tumor
(RECIST) were not used in this study. Local failure was considered to
have occurred when enlargement of the local tumor continued for>
6months on follow-up CT scans or was conﬁrmed histologically. FDG-
PET/CT was recommended when local failure was suspected, but this
was not mandatory. Absence of local failure was deﬁned as locally
controlled disease. No chemotherapy was allowed after SBRT until re-
currence. After conﬁrmation of any failures, salvage treatment was al-
lowed.
2.3. Statistical analysis and ethical considerations
Because the 3-year OS was 78% in patients with a tumor diameter
≤30mm in the national retrospective SBRT study mentioned above
[5], we estimated that the 3-year OS for patients in this prospective
observation study would be 80%. The sample size was determined to be
62 by a precision basis so that the 95% conﬁdence interval (CI) for the
estimated 3-year OS would be±10% around the expected value of
80%.
OS, PFS and LC were calculated using the Kaplan-Meier method.
The log-rank test was used to calculate statistical signiﬁcance between
diﬀerences. Multivariate analysis was performed using a Cox propor-
tional hazards regression model. A value of p < 0.05 was considered
statistically signiﬁcant. All the analyses were performed with SAS re-
lease 9.4 (SAS Institute, Cary, NC).
The study protocol was accepted by 11 institutions in Japan in July
2009. Nine of the 11 were involved in JCOG 0403 [4] and JCOG 0702
[6,7]; therefore, the SBRT quality control (QA) was completed already
[10]. For the other 2 institutions, we added a survey for their QA
program for SBRT and accepted them. The patients were recruited from
August 2009 to August 2014, and the data were analyzed in August




3.1. Survival and local control
Sixty-two patients from 11 institutions were enrolled. Their median
age was 80 years. The tumor sizes ranged from 9 to 30mm in diameter
(median 18mm). Patient characteristics are shown in Table 1.
Of the 62 patients, 14 died; 8 of these deaths were from causes
unrelated to lung cancer. Thus, the proportion of primary cancer death
was 42.9% (6/14). The median follow-up was 55 months and ranged
from 12 to 90 months. For patients with a follow-up period less than 36
months, four patients were lost to follow-up at 12, 18, 20 and 25
months after the treatment.
The 3-year OS was 83.3% (95% CI 71.1–90.7%) (Fig. 1). The 3-year
PFS and LC were 69.7% and 93.5% (Fig. 1), respectively. Univariate
analysis showed that only age (< /≥80) was a prognostic factor for
OS (p= .039, Fig. 2); thus, no other parameters were signiﬁcant
prognostic factors for OS (Table 2). There were no signiﬁcant diﬀer-
ences in operable (n=43) or inoperable (n= 19), GGN (n=15) or
non-GGN (n= 47), or tumor size larger (n= 27) or smaller than
(n=35) 20mm. Age (< /≥80) remained a signiﬁcant prognostic
factor for OS even in multivariate analysis (HR 1.020-11.276,
p= .046). Additionally, the 3-year OS for patients younger than 75
years with a median age of 68 years was 94.7% (95% CI 68.1–99.2%).
However, for patients 75 years or older with a median age of 82 years,
the 3-year OS was 78.0% (95% CI 62.0–88.0%) (Fig. 2). Univariate
analysis showed that age (< /≥ 75) was a prognostic factor for OS
(p= .021) as well.
A total of 14 failures were observed. Local failure, regional lymph
node metastases and distant metastases occurred in 4 (6.4%), 3 (4.8%)
and 11 (17.7%) patients, respectively. The combination of failure pat-
terns is shown in Table 3. Those with distant metastases include 9 pa-
tients with pleural dissemination, 3 in the lung, 2 in the liver and 1 in
the brain and muscle.
3.2. Toxicities
Acute (≤56 days) and late (≥57 days) toxicities were prospectively
observed and evaluated. No acute toxicities grade 3 or higher occurred.
Grade 3 and 4 late toxicities were observed in 8 (12.9%) and 1 (1.6%)

















Reason for pathological unproven
Nondiagnostic biopsy undergone 33
Biopsy refused 19















Forced expiratory volume 1.0 (ml)
Median 1645
Range 740–2890
Fig. 1. Kaplan-Meier curve of the overall survival rate (A), progression-free
survival (B), and local control rate (C) for all the patients.
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regarding late toxicities are shown in Table 4. There was grade 3 dys-
pnea in 7 (11.2%) patients, radiation pneumonitis in 3 (4.8%) patients
and hypoxia in 2 (3.2%) patients. There was grade 4 dyspnea in 1
(1.6%) patient, radiation pneumonitis in 1 (1.6%) patient, and hypoxia
in 1 (1.6%) patient. No other late adverse eﬀects of grade 3 or higher
were observed.
4. Discussion
The results of this study should be carefully evaluated because GGNs
are included. A GGN with a solid component is known to exhibit similar
results as stage I non-small cell lung cancer (NSCLC) after surgery.
Noguchi et al. showed in 1995 that surgery for GGNs 2 cm or smaller
with a solid component resulted in a 5-year OS of 74.8%, with a 3-year
OS of approximately 80% [11]. In 2013, Asamura et al. recommended
major surgical resection for patients with GGNs ≤30mm with a con-
solidation to a tumor ratio> 0.5 by CT based on achieving a 5-year OS
of 88.9%, with a 3-year OS of 94% for patients under 75 years old with
a median age of 62 years [12]. Regarding pure GGNs without a solid
component, Godoy and Naidich recommended surgical resection for
pure GGNs 10mm or larger [8]. Lim et al. recently conﬁrmed that 39%
of pure GGNs 10mm or larger by CT are invasive adenocarcinomas by
pathology [9]. Regarding pure GGNs without a solid component, be-
cause we added GGN enlargement by sequential CT for pure GGN
10mm or larger in the inclusion criteria, the incidence of invasive
cancer may be higher in this study. Consequently, there were no sig-
niﬁcant diﬀerences between the outcomes of patients with GGNs and
those with non-GGN tumors in this study. The 3-year OS for patients
under 75 years old with a median age of 68 years was 94.7% (95% CI
68.1–99.2%), which is consistent with the estimated 3 year-OS in a
surgical study by Asanuma et al. These ﬁndings, in addition to
Fig. 2. Kaplan-Meier curve of the patients older and younger than 80 years old.
Signiﬁcant diﬀerences were observed (p= .046) between the two groups (A).
Kaplan-Meier curve of the patients older and younger than 75 years old.
Signiﬁcant diﬀerences were observed (p= .021) between the two groups (B).
Table 2
Univariate and multivariate analyses for overall survival.












≥80 31 76·2 66·0 0·039* 3·392
(1·020−11·276)
0·046*
<80 31 86·2 86·2
Gender
Female 22 77·3 77·3 0·662 0·265
(0·034−2·061)
0·205
Male 40 86·7 75·6
Performance status
0 44 83·9 77·7 0·486 0·984
(0·245−3·953)
0·982
1/2 18 82·1 74·6
Smoking
No 19 74·4 68·2 0·147 6·45
(0·668−62·283)
0·107












No 47 80·0 74·5 0·272 2·166
(0·404−11·598)
0·367
Yes 15 93·3 84·0
Tumor size (mm)
≥20 27 76·6 72·4 0·541 1·678
(0·466−6·050)
0·429
<20 35 88·4 79·9
Medical condition
Inoperable 19 78·2 78·2 0·892 1·023
(0·274−3·819)
0·973
Operable 43 85·6 76·8
Abbreviations: UVA=univariate analysis, MVA=multivariate analysis,
HR=hazard ratio.





















Grade4 (n= 1, 1.6%)
Dyspnea+Hypoxia+Pneumonitis 1
Grade5 (n= 0) 0
Total 9
Abbreviation: LN= lymph nod.
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recommendations by Asanuma et al. and Godoy and Naidich, suggest
that the GGN inclusion criteria in this study were reasonable.
We adapted positive FDG PET results as eligibility criteria for non-
GGN. Before the introduction of FDG PET in the 1990s, the percentage
of malignant disease for solitary lung nodules detected by plain chest X-
ray or CT examination was 50–75% [13–16]. However, a meta-analysis
in 2001 by Gould et al. showed that FDG-PET has 77.8% speciﬁcity,
96.8% sensitivity, and 91.2% accuracy for diagnosing primary lung
cancer [17]. By adding tumor enlargement by sequential CT examina-
tion and a positive FDG PET examination in the inclusion criteria, the
likelihood of invasive cancer should be higher than 77.8% in this study.
There were 12.9% grade 3 and 1.6% grade 4 late toxicity events in
our series. JCOG0403 showed 10.6% grade 3 and 1.9% grade 4 late
toxicities in inoperable patients and 8.9% grade 3 and 1.2% grade 4
toxicities in total after SBRT for pathologically proven stage I NSCLC
[4]. The similarity between our study and JCOG0403 is reasonable, as
we used the same technology. Sawabata et al. also reported that after
surgical resection of NSCLC, postoperative complications grade 4 or
higher were observed in 4.5% in 11,663 operable patients with 0.4%
operative death (death within 30 days) and 0.4% hospital death (death
after 30 days or more) treated during 2004 in Japan [18]. For operable
patients who refuse surgery, grade 4 or higher late toxicity after SBRT
was suggested to be lower than the surgical series, although the latter
included patients with higher clinical stages. Solaini et al. reported that
the risk of complications after surgical biopsy ranges from 3.3–13.4%,
although its severity varies [19]. Considering that the median age was
80 years and the medial forced expiratory volume 1.0 (ml) was 1645ml
distributed from 740 to 2890ml in total, this study suggested that SBRT
has a risk of adverse reaction nearly equal to biopsy for patients with
inoperable tumors.
It would be informative to compare the results of this study with the
results of pathologically proven SBRT patients. In the JCOG0403 study,
in which SBRT was used for pathologically proven T1N0M0 non-small
cell lung cancer, the 3-year overall survival rate (OS) was 76.5% (95%
CI 64.0–85.1%) for operable patients and 59.9% (95% conﬁdence in-
terval 49.6–68.8%) for inoperable patients [4]. The 83.3% (95% CI
71.1–90.7%) 3-year OS in this study seems to be superior to that of the
JCOG0403 study, but it must be noted that the distribution of the ECOG
performance status of the patients was better in this series than that in
JCOG0403; 71% of the patients had PS 0 in this series vs 39% of op-
erable patients in JCOG0403 and 61% of inoperable patients in
JCOG0403.
There is no reliable data describing the outcome after watchful
waiting for the same patient cohort patients. As a reference, a study
using the Surveillance Epidemiology and End Results (SEER) database
in the USA showed that the OS for no treatment (n= 291) in patients
80 years or older with Stage I NSCLC was 28.9% (95% CI 23.3–34.7%)
at 2 years [20]. However, the medical condition of the patients might
have been considerably diﬀerent from this study. As another reference,
the 3-year OS was estimated to be 91% in patients with a median age of
67 years with clinical Stage IA NSCLC (n=6295) who had received
surgery in Japan in 2004 [18]. Chang et al. reported the outcome of
SBRT and lobectomy for operable stage I NSCLC [21]. The 3-year OS
was 95% in the SBRT group with a median age of 67 years and 79% in
the surgery group with a median age of 67 years. The present results for
patients younger than 75 years old are similar to the Japanese surgical
study and Chang et al.’s study on age distribution as well as treatment
outcome. For patients 75 years or older, the 3-year OS was 78.0% (95%
CI 62.0-88.0%) with a median age of 82 years in the present study.
Miyazaki et al. recently reported that SBRT treatment and surgery ex-
hibit similar results for patients 80 years or older with Stage I NSCLC
using propensity score matching [22]. Taremi et al. reported results
using SBRT for medically inoperable lung cancer regardless of patho-
logical conﬁrmation [23] and observed no signiﬁcant diﬀerences in OS
among patients with pathologically conﬁrmed cancer. In fact, recent
reports regarding SBRT often contain patients with small lung lesions
clinically diagnosed as primary lung cancer without a precise deﬁnition
of diagnostic criteria [23–26]. This study conﬁrmed that OS after SBRT
in patients with small lung lesions clinically diagnosed as primary lung
cancer is similar to OS after surgery and SBRT in patients with patho-
logically proven stage IA NSCLC.
In patterns of failure analysis, distant metastases were the most
frequently observed event, which was similar to the adverse events
observed in JCOG0403 [4]. Distant metastases were observed in 17.7%
of patients, whereas local failure and regional lymph node metastases
observed in 6.4% and 4.8% of patients, respectively. The low local and
regional relapse rate in addition to the low adverse reaction rates in this
study suggested that a total dose of 48 Gy at the isocenter administered
in 4 fractions only to the primary tumor is suﬃcient. Additional
treatment to reduce distant metastasis is an issue requiring discussion.
Patients with solid tumors 10mm or smaller were generally in-
eligible for this study because of the inclusion criteria. In fact, only one
patient with a lesion smaller than 10mm (9mm) entered this study
because of positive FDG PET results and enlargement by sequential CT
examination. A more sophisticated non-invasive diagnostic method is
required for lesions 10mm or less in diameter because FDG-PET/CT has
a lower sensitivity and speciﬁcity for small lesions [27–30].
5. Conclusions
SBRT to treat small lung lesions clinically diagnosed as primary lung
cancer is eﬀective and safe as long as strict eligibility and exclusion
criteria are adapted. This treatment can be considered an alternative
treatment option to watchful waiting or open surgery for patients with
small lung lesions clinically diagnosed as primary lung cancer by
radiological examination. A prospective interventional study is required
to conﬁrm our ﬁndings.
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